Advertisement

Topics

PubMed Journals Articles About "(Val)Ganciclovir TDM In Transplant Recipients" RSS

14:23 EST 23rd February 2019 | BioPortfolio

(Val)Ganciclovir TDM In Transplant Recipients PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest (Val)Ganciclovir TDM In Transplant Recipients articles that have been published worldwide.

More Information about "(Val)Ganciclovir TDM In Transplant Recipients" on BioPortfolio

We have published hundreds of (Val)Ganciclovir TDM In Transplant Recipients news stories on BioPortfolio along with dozens of (Val)Ganciclovir TDM In Transplant Recipients Clinical Trials and PubMed Articles about (Val)Ganciclovir TDM In Transplant Recipients for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of (Val)Ganciclovir TDM In Transplant Recipients Companies in our database. You can also find out about relevant (Val)Ganciclovir TDM In Transplant Recipients Drugs and Medications on this site too.

Showing "Ganciclovir Transplant Recipients" PubMed Articles 1–25 of 1,600+

Cryptococcal infection in lung transplant recipients: a five-year retrospective review at an Australian transplant centre.

Cryptococcosis is a common invasive fungal infection (IFI) in solid organ transplant (SOT) recipients. Little is known about cryptococcosis in lung transplant (LTx) recipients despite having one of the highest risks of infection.


Adjunctive Use of Cidofovir and Intravenous Immunoglobulin to Treat Invasive Adenoviral Disease in Solid Organ Transplant Recipients.

Infections with adenoviruses can result in considerable mortality and morbidity in solid organ transplant recipients. Standard therapy for adenovirus infections in transplant recipients is not established. At our institution, intravenous cidofovir and immunoglobulin have been used to treat disseminated or invasive adenovirus in solid organ and hematopoietic stem cell transplant recipients.

Longitudinal Changes in Kidney Function Following Heart Transplantation: Stanford Experience.

Many heart transplant recipients experience declining kidney function following transplantation. We aimed to quantify change in kidney function in heart transplant recipients stratified by pre-transplant kidney function. 230 adult heart transplant recipients between May 1, 2008 and December 31, 2014 were evaluated for up to 5 years post-transplant (median 1 year). Using 19,398 total eGFR assessments, we evaluated trends in estimated glomerular filtration rate (eGFR) in recipients with normal/near normal (e...


Repeat kidney transplant recipients with active rejection have elevated donor-derived cell-free DNA.

In 2015, 13% of recipients of kidney transplants in the United States were repeat transplants for prior allograft failure (1). These repeat kidney transplant recipients (RKTR) have inferior graft survival and a higher risk of rejection to that of single kidney transplant recipients (SKTR) (1, 2). In spite of these risks, transplant patients benefit from a repeat transplant compared to dialysis support (3). The use of noninvasive biomarkers of allograft injury may optimize the care of RKTR. This article is p...

Management of organ transplant recipients attending a high-throughput skin cancer surgery and surveillance clinic in Queensland.

The incidence of skin cancer in organ transplant recipients (OTRs) is very high due mainly to long-term immunosuppressive therapy. The problem is particularly severe for organ transplant recipients living in Queensland, Australia, resulting in significant mortality.

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.

Cytomegalovirus (CMV) infections that are refractory or resistant (RR) to available antivirals ([val]ganciclovir, foscarnet, cidofovir) are associated with higher mortality in transplant patients. Maribavir is active against RR CMV strains.

Prevalence and characteristics of hepatitis E virus infection in kidney transplant recipients: a single-center experience in Japan.

Hepatitis E virus (HEV) infection can lead to chronic hepatitis in solid organ transplant recipients. To investigate whether HEV infection influences outcomes following kidney transplantation, we examined the prevalence of HEV infection and clinical characteristics of kidney transplant recipients in our hospital.

Impact of Antiretroviral Regimen on Renal Transplant Outcomes in HIV-Infected Recipients.

Protease inhibitors (PI) pose a challenge post-transplant due to significant drug interactions with calcineurin inhibitors, prompting many clinicians to convert patients to non-interacting regimens prior to transplant. The purpose of this study was to examine the impact of PI-based regimens on graft outcomes in HIV-infected renal transplant recipients.

Risk of incident gout following kidney transplant recipients: A retrospective cohort study.

Gout is a common complication in kidney transplant recipients. This study evaluated the association between kidney transplant recipients and the long-term risk of incident gout.

Human Herpesvirus 6B in the Transplant Recipient: When to Worry, When to Act.

Human herpesvirus 6B (HHV-6B) is a ubiquitous pathogen that infects most individuals before the age of three years. HHV-6B reactivates in approximately 40% of transplant recipients where it has been associated with a number of important outcomes, especially in allogeneic transplant recipients. This article will review the epidemiology, clinical manifestations, diagnosis, and treatment of HHV-6B infection.

Human Herpesvirus 6B in the Transplant Recipient: When to Worry, When to Act.

Human herpesvirus 6B (HHV-6B) is a ubiquitous pathogen that infects most individuals before the age of three years. HHV-6B reactivates in approximately 40% of transplant recipients where it has been associated with a number of important outcomes, especially in allogeneic transplant recipients. This article will review the epidemiology, clinical manifestations, diagnosis, and treatment of HHV-6B infection.

Human Herpesvirus 6B in the Transplant Recipient: When to Worry, When to Act.

Human herpesvirus 6B (HHV-6B) is a ubiquitous pathogen that infects most individuals before the age of three years. HHV-6B reactivates in approximately 40% of transplant recipients where it has been associated with a number of important outcomes, especially in allogeneic transplant recipients. This article will review the epidemiology, clinical manifestations, diagnosis, and treatment of HHV-6B infection.

Human Herpesvirus 6B in the Transplant Recipient: When to Worry, When to Act.

Human herpesvirus 6B (HHV-6B) is a ubiquitous pathogen that infects most individuals before the age of three years. HHV-6B reactivates in approximately 40% of transplant recipients where it has been associated with a number of important outcomes, especially in allogeneic transplant recipients. This article will review the epidemiology, clinical manifestations, diagnosis, and treatment of HHV-6B infection.

Human Herpesvirus 6B in the Transplant Recipient: When to Worry, When to Act.

Human herpesvirus 6B (HHV-6B) is a ubiquitous pathogen that infects most individuals before the age of three years. HHV-6B reactivates in approximately 40% of transplant recipients where it has been associated with a number of important outcomes, especially in allogeneic transplant recipients. This article will review the epidemiology, clinical manifestations, diagnosis, and treatment of HHV-6B infection.

Efficacy of Brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients.

Allogeneic hematopoietic cell transplant (HCT) recipients are at risk for herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Routine prophylaxis with acyclovir is recommended during periods of immunosuppression. Brincidofovir (BCV, CMX001), a lipid conjugate of cidofovir, is active in vitro activity against HSV/VZV, but has not been formally studied for HSV/VZV prophylaxis. We report our clinical experience of BCV for HSV/VZV prophylaxis in HCT recipients.

Medication adherence in renal transplant recipients: A latent variable model of psychosocial and neurocognitive predictors.

Estimates indicate that 20-70% of renal transplant recipients are medication non-adherent, significantly increasing the risk of organ rejection. Medication adherence is negatively impacted by lower everyday problem solving ability, and associations between depressive symptoms, self-efficacy, and adherence are reported in renal transplant recipients. Nonetheless, to date, these associations have not been examined concurrently. Given the relationship between non-adherence and organ rejection, it is critical t...

Early Hospital Readmission in Older and Younger Kidney Transplant Recipients.

Up to 31% of kidney transplant (KT) recipients experience early hospital readmission (EHR). We hypothesized that EHR among older KT recipients is higher than younger recipients due to increased comorbidities and higher prevalence of frailty.

Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.

CMV is associated with adverse effects in renal transplant recipients. The objective of this study was to characterize the incidence and timing of CMV and EBV infections in relation to valGCV prophylaxis in a pediatric renal transplant cohort.

Detection of engraftment of donor-derived antibody producing cells in a lung transplant recipient by anti-cytomegalovirus IgG avidity test.

Transplant recipients become immunocompromised through the use of immunosuppressive therapy to prevent allograft rejection. These recipients readily experience human cytomegalovirus (CMV) infection or reactivation. Therefore, CMV represents a life-threatening pathogen in transplant recipients. To demonstrate the serostatus and course of IgG maturation against CMV in transplant patients, we measured the transition of anti-CMV IgG and its affinity (avidity index; AI) as criteria for antibody maturation. Among...

Pharmacokinetics of Daclatasvir, Sofosbuvir and GS-331007 in a Prospective Cohort of HCV positive Kidney Transplant Recipients.

Limited data exist on the pharmacokinetic profile of novel direct acting antivirals in kidney transplant recipients. Daclatasvir is primarily eliminated via the biliary route and sofosbuvir via the renal route; here we report the pharmacokinetic profile of combined treatment with these compounds in a prospective study of hepatitis C virus positive kidney transplant recipients (EudraCT: 2014-004551-32).

Safety and Efficacy of Methenamine Hippurate for the Prevention of Recurrent Urinary Tract Infections in Adult Renal Transplant Recipients: A Single Center, Retrospective Study.

Recurrent urinary tract infections (UTI) are an important cause of morbidity and mortality in renal transplant recipients (RTR).

Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens.

Ribavirin is used in the treatment of respiratory paramyxovirus infection in lung transplant recipients; however, its pharmacokinetic profile in the transplant population is unknown despite the potential for alterations due to underlying pathology. Furthermore, the ability of current regimens to meet exposure targets has not been established.

Kinetics of antibody response to influenza vaccination in renal transplant recipients.

Annual vaccination is routinely used in organ transplant recipients for immunization against seasonal influenza. However, detailed analysis of the kinetics of vaccine-induced immune responses in this population is lacking. In this study, we investigated the kinetics of vaccine strains-specific antibody responses to trivalent influenza vaccine in a group of renal transplant recipients and a control group. First, we found that the geometric mean hemagglutination inhibition titer against all 3 vaccine strains ...

Knowledge of Chronic Kidney Disease among Liver Transplant Recipients.

Chronic kidney disease (CKD) after liver transplant (LT) is an important co-morbidity that negatively affects patient and graft survival. Additionally, it adds to resource utilization in LT recipients leading to increased healthcare costs. Although LT recipients have established framework of care and access to education as a part of transplant process, there may be significant modifiable gaps in their knowledge and understanding of CKD after LT. This article is protected by copyright. All rights reserved.

A National Survey of Valganciclovir Dosing Strategies in Pediatric Organ Transplant Recipients.

Data remain limited on the most appropriate valganciclovir (VGCV) dosing strategy for cytomegalovirus (CMV) prophylaxis and treatment in pediatric organ transplant recipients. Therefore, the objective of this study was to describe methods used to calculate VGCV dosing among pediatric transplant centers.


Advertisement
Quick Search
Advertisement
Advertisement